Role of the CD28 receptor in T-cell activation
dc.contributor.author | June, Carl H. | en_US |
dc.contributor.author | Ledbetter, Jeffrey A. | en_US |
dc.contributor.author | Linsley, Peter S. | en_US |
dc.contributor.author | Thompson, Craig B. | en_US |
dc.date.accessioned | 2006-04-10T13:54:41Z | |
dc.date.available | 2006-04-10T13:54:41Z | |
dc.date.issued | 1990 | en_US |
dc.identifier.citation | June, Carl H., Ledbetter, Jeffrey A., Linsley, Peter S., Thompson, Craig B. (1990)."Role of the CD28 receptor in T-cell activation." Immunology Today 11(): 211-216. <http://hdl.handle.net/2027.42/28838> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6VHW-4847DBJ-49/2/8203f5b041926a7b0be66e5fec9d1554 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/28838 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2162180&dopt=citation | en_US |
dc.description.abstract | Antigen-specific T-cell activation is initiated through the T-cell receptor. Recent evidence has shown that a number of additional T-cell surface receptors serve to regulate the responses of antigen-activated T cells. One such molecule, CD28, is a member of a heterophilic cell adhesion complex, and is the receptor for the B-cell-restricted B7/BB-1 antigen. As Carl June, Jeffrey Ledbetter, Peter Linsley and Craig Thompson review here, CD28 serves as the surface component of a novel signal transduction pathway that modulates T-cell lymphokine production and increases the resistance of cell responses to various immunosuppressive agents. | en_US |
dc.format.extent | 987446 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | Role of the CD28 receptor in T-cell activation | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA | en_US |
dc.contributor.affiliationother | Naval Medical Research Institute, Bethesda, MD 20814, USA | en_US |
dc.contributor.affiliationother | Oncogen Corp., Seattle, WA 98121, USA | en_US |
dc.contributor.affiliationother | Oncogen Corp., Seattle, WA 98121, USA | en_US |
dc.identifier.pmid | 2162180 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/28838/1/0000673.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0167-5699(90)90085-N | en_US |
dc.identifier.source | Immunology Today | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.